Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
about
Renal Cancer Stem Cells: Characterization and Targeted TherapiesNK Cells in HIV DiseaseThe Application of Natural Killer Cell Immunotherapy for the Treatment of CancerAdoptive T-Cell ImmunotherapyImmunotherapy of Childhood SarcomasEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityAnticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyAdoptive T-cell therapy for cancer: The era of engineered T cellsInsufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cellsImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationTrial Watch-Immunostimulation with cytokines in cancer therapyImmunological and Translational Aspects of NK Cell-Based Antitumor ImmunotherapiesImproving natural killer cell cancer immunotherapyIL15 and T-cell Stemness in T-cell-Based Cancer ImmunotherapyThe shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapyTumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine.Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.Interleukin-2 Receptor β Thr-450 Phosphorylation Is a Positive Regulator for Receptor Complex Stability and Activation of Signaling Molecules.IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.Deficiency of Interleukin-15 Confers Resistance to Obesity by Diminishing Inflammation and Enhancing the Thermogenic Function of Adipose Tissues.Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes.Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal ModelsCommon gamma chain cytokines in combinatorial immune strategies against cancerHigh dose CD11c-driven IL15 is sufficient to drive NK cell maturation and anti-tumor activity in a trans-presentation independent mannerAntibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.Modeling the pharmacokinetic-pharmacodynamic relationship of the monoclonal anti-macaque-IL-15 antibody Hu714MuXHu in cynomolgus monkeys.Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor ImmunityLocal Immune Stimulation by Intravesical Instillation of Baculovirus to Enable Bladder Cancer Therapy.IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cellsSystemic and intratumoral balances between monocytes/macrophages and lymphocytes predict prognosis in hepatocellular carcinoma patients after surgery.Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cellsIdentification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposureAnalyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune PathwaysIL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM).
P2860
Q26746970-F2FC3D28-7912-47DD-B03D-B6D4E45A5017Q26752833-331B7178-0FCE-4DFA-8591-ADA00DB1EE2CQ26774678-FAA9FEE5-09EE-49DA-BE3E-6B74E59062F3Q26782845-A0E8CA9B-C3AD-46B8-BAC2-7B21DF022E25Q26795369-97D19488-3D8E-41F9-AA29-15D2A87436D7Q26796313-05D1A499-0CC5-4942-BBD5-4D2CCA52B2E9Q26796316-946404BA-5D5D-4554-930E-6FD851408F82Q26797345-BBF17718-3B04-4DE9-9B08-943765B44F68Q26800611-027CCA54-87B8-4997-B900-8FFC6E3B3F43Q28068375-2404969F-05F8-4ADB-B714-F121C15F1821Q28068378-85B581F4-B137-4D94-B198-05CB226FC9E4Q28078725-70FF17AC-93F5-46E2-80C6-B59B11DB2003Q28079180-28007EDC-0711-4F1E-82D7-096F7BD9F235Q28087719-D3637950-1FB2-4BC7-A30C-C7BB18587133Q28088543-4CE3D14C-9106-4C8B-B10C-50700C222B17Q28088784-44F7AB05-D957-444A-87F1-62CB025B0442Q30830664-7B0EEFE1-4CF2-42CF-8B80-9B2075A823EDQ33861833-FF4F748E-62D1-4980-B7D5-850AE966B480Q35600095-33D498C9-FCCB-44D0-B16B-C8B053317326Q35710332-0FF608C9-7212-41EE-A00D-F9C6B639C073Q35978264-FDC3C487-28CD-46F1-968E-A900C516775CQ35979037-75E177E6-00A6-4960-A00E-BEAF28F7A427Q36147727-0E83D442-63DF-4B41-B866-9493707BA548Q36245682-E6F4BD96-61C8-436A-83B0-E9455305E675Q36436914-2B71A3A8-B673-4A38-8925-4262652955F1Q36455872-93318AE9-34BD-4887-8D61-252F1514DC82Q36517092-C7CD9637-8D5C-4DD2-8B0B-83105EB48A8FQ36539682-9161DF52-B7A1-48DF-AEBF-88A2BCD5717DQ36648845-64A803BB-D094-466C-BD36-2B2675C0D48CQ36884768-882ADC62-79C3-4D32-8691-0F705D871741Q36980415-F0C732D1-AC02-49BF-9721-74422F15D45BQ37085973-EAEE70E6-5943-4819-B6D5-81387930F5B6Q37261189-B0DC1F69-9796-4238-9B67-6B739708B50EQ37294760-AD714F62-488F-46CC-AA0A-8650651797E4Q37327632-31E57A35-0001-4688-ACD6-23EDCE255B46Q37474007-8F5A946C-B954-484F-949A-04A229DAE2CDQ37580158-1879C150-0A9F-49BE-98D9-C999E05AFADFQ37658381-89F5A98C-F3D3-49D1-8BBA-4FEC65E5A2EEQ37690959-A387F38E-8177-4A76-8FCC-2595DAD4B4BFQ37709365-C052CAA7-4C13-45C1-B17C-A9C3BF4D442B
P2860
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Redistribution, hyperprolifera ...... in-15 in patients with cancer.
@ast
Redistribution, hyperprolifera ...... in-15 in patients with cancer.
@en
type
label
Redistribution, hyperprolifera ...... in-15 in patients with cancer.
@ast
Redistribution, hyperprolifera ...... in-15 in patients with cancer.
@en
prefLabel
Redistribution, hyperprolifera ...... in-15 in patients with cancer.
@ast
Redistribution, hyperprolifera ...... in-15 in patients with cancer.
@en
P2093
P2860
P356
P1476
Redistribution, hyperprolifera ...... in-15 in patients with cancer.
@en
P2093
Antonio Tito Fojo
Bonita R Bryant
Carolyn K Goldman
Cody J Peer
Donn M Stewart
Enrico Lugli
H Clifford Lane
Hugh C Welles
Jason L Yovandich
Jean M Decker
P2860
P356
10.1200/JCO.2014.57.3329
P407
P577
2014-11-17T00:00:00Z